Pujol, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., . . . Souquet, P. (2019). A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. Journal of Thoracic Oncology, 14(5), 903-913. https://doi.org/10.1016/j.jtho.2019.01.008

Pujol, Jean-Louis, et al. "A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial." Journal of Thoracic Oncology 14, no. 5 (2019): 903-913. https://doi.org/10.1016/j.jtho.2019.01.008.

Pujol, Jean-Louis, et al. "A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial." Journal of Thoracic Oncology, vol. 14, no. 5, 2019, pp. 903-913, https://doi.org/10.1016/j.jtho.2019.01.008.